GeneSight Mental Health Monitor Media Kit: Depression Disconnect
Depression Disconnect: GeneSight® Mental Health Monitor Shows Misunderstanding of Depression and Treatment
New poll shows 83% of people with depression agree life would be easier if others could understand their depression
SALT LAKE CITY, April 28, 2021 – In a new nationwide poll, the GeneSight® Mental Health Monitorfound that 83% of people with depression agree that life would be easier if others could understand their depression. Yet, most people who have not experienced depression may not be able to understand the challenges, including its treatment.
Michael Jablonski, Ph.D., M.S., vice president of medical affairs for the GeneSight test at Myriad Genetics, reviews a GeneSight Psychotropic report. The GeneSight Mental Health Monitor national survey found that 7 in 10 would feel “hopeful” if their doctor recommended genetic testing as part of their treatment plan.
Amanda Lange swabs her cheek to complete the GeneSight Psychotropic test. The test was ordered by her doctor to get information about which medications may require dose adjustments, may be less likely to work, or may have an increased risk of side effects based on her genetic makeup. In a new nationwide poll, the GeneSight Mental Health Monitor found 7 in 10 adults with depression would feel “hopeful” if their doctor recommended genetic testing as part of their treatment plan.
The GeneSight Mental Health Monitor is a nationwide survey of U.S. adults conducted by ACUPOLL Precision Research, Inc. in March 2021. The survey was conducted among a statistically representative sample of U.S. adults age 18+, including a U.S. representative sample of adults who have been diagnosed with depression. The margin of error in survey results for the total base population at a 95% confidence interval is +/- 3%.